Phase 3 Readout
HURA: Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Ther
December 30, 2032 · ifx-hu2. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 30, 2032
- Company
- TuHURA Biosciences, Inc./NV (HURA)
- Drug
- ifx-hu2
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Ther
- Drug
- ifx-hu2
- Indication
- Advanced Or Metastatic Merkel Cell Carcinoma